Information About Geographic Areas

12 Months Ended

Dec. 31, 2021

Segment Reporting [Abstract]

Information About Geographic Areas

Information About Geographic AreasWe operate in one reporting segment that creates, manufactures, and markets a range of products and services, including instruments, consumables, reagents and software that are used by researchers and clinical labs worldwide. Our chief executive officer manages our operations and evaluates our financial performance on a consolidated basis. For purposes of allocating resources and evaluating regional financial performance, our chief executive officer reviews separate sales information for the different regions of the world. Our general and administrative expenses and our research and development expenses are not allocated to any specific region. Most of our principal operations, other than manufacturing, and our decision-making functions are located at our corporate headquarters in the United States.

A summary table of our revenue by geographic areas of our customers and by product and services for the years ended December 31, 2021, 2020 and 2019 is included in Note 6 to the consolidated financial statements.

Revenue from customers in the United States represented $60.2 million, or 46%, of total revenues for the year ended December 31, 2021. Revenue from domestic customers represented $72.0 million, or 52%, of total revenues for the year ended December 31, 2020 and $43.4 million, or 37%, for the year ended December 31, 2019.

Revenue from customers in China were less than 10% of total revenues for the year ended December 31, 2021 and 2020. Revenue from customers in China represented $15.4 million, or 13%, of total revenues for the year ended December 31, 2019. With the exception of China, no other foreign country or jurisdiction had revenue in excess of 10% of our total revenue during the years 2021, 2020 and 2019.

No individual customer represented more than 10% of our total revenues for the fiscal years ended December 31, 2021, 2020, and 2019. Revenues from our five largest customers were 23% for the both the years ended December 31, 2021 and 2020, and 17% for 2019.

We had long-lived assets consisting of property and equipment, net of accumulated depreciation, and operating lease ROU assets, net of accumulated amortization, in the following geographic areas for each year presented (in thousands):

	December 31,
	2021		2020
United States	$	34,497	$	35,188
Singapore	23,732		12,195
Canada	5,597		6,456
Asia-Pacific	804		1,048
EMEA	523		758
Total	$	65,153	$	55,645

The increase in long-lived assets in Singapore is attributable to capital expenditures funded by the NIH Contract (see Note 4).